Biosimilars Hands
Biosimilars Hands

A WORLD OF CARE

Biologic medicines have become the standard of care for many serious diseases like cancer, autoimmune disorders and diabetes.

biosimilars without borders

Mylan's belief is that 7 billion people across the globe deserve access to the treatments they need. As one part of this broader cause, we are working to make biologics more accessible.

What is Biosimilar
What is Biosimilar
What is Biosimilar
What is Biosimilar
What is Biosimilar

WHAT ARE BIOSIMILARS

marvels of modern science

Biologics have revolutionized the treatment of many diseases. Biosimilar medicines offer physicians additional therapeutic options to essential, but often expensive biologic products.
Unlike conventional medicines, which are made up of chemical compounds, biologics are complex products composed of proteins, sugars or nucleic acids, or may be living entities such as cells and tissues.

Biologics are highly complex and often expensive therapies.

A biosimilar is a biologic deemed highly similar to an already approved biologic medicine, known as a reference product. This similarity is confirmed through a number of tests, both in the lab and in clinical research.

A biosimilar manufacturer must demonstrate that its proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and effectiveness.

  • WHAT IS A BIOSIMILAR?

    Biologics are highly complex and often expensive therapies.

    A biosimilar is a biologic deemed highly similar to an already approved biologic medicine, known as a reference product. This similarity is confirmed through a number of tests, both in the lab and in clinical research.

    A biosimilar manufacturer must demonstrate that its proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and effectiveness.

Biosimilars Reach
Biosimilars Reach
Biosimilars Reach

EXPANDING ACCESS

we reach people

The most advanced drugs are of no use if patients don’t have access to them. Biologics are a case in point.

Only 2% of the U.S. population uses biologics, but they account for 40% of prescription drug spending. Of the top 20 most costly drugs in the world, 12 of them are biologics, representing ~$100 billion of the ~$153 billion spent on these medicines; Mylan has 9 of these products on the market or in its global product pipeline.

Global Reach

There is an urgent need for biologics in many underserved regions, countries and emerging markets around the world.

Mylan has successfully introduced biosimilars in over 25 countries. What others hope to do in the future, Mylan is delivering today.

For nearly 60 years, Mylan’s mission has been to provide access to medicine. Today our workforce of ~35,000 serves patients in >165 countries and territories, and we offer a growing portfolio of more than 7,500 medicines, including branded, generic and consumer health products. You may not realize that Mylan provides ~69 billion doses of medicine annually.

Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics, and potentially increasing access to treatment. It's not just patients who benefit - governments and insurers do, too.

  • NO MATTER WHERE

    OVER 25 COUNTRIES GLOBALLY

    There is an urgent need for biologics in many underserved regions, countries and emerging markets around the world.

    Mylan has successfully introduced biosimilars in over 25 countries. What others hope to do in the future, Mylan is delivering today.

  • ITS WHAT WE DO

    For nearly 60 years, Mylan’s mission has been to provide access to medicine. Today our workforce of ~35,000 serves patients in >165 countries and territories, and we offer a growing portfolio of more than 7,500 medicines, including branded, generic and over-the-counter products. You may not realize that Mylan provides ~69 billion doses of medicine annually.

    Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics, and potentially increasing access to treatment. It's not just patients who benefit - governments and insurers do, too.

Biosimilars Value
Biosimilars Value

A COMMITMENT TO BIOSIMILARS

biosimilars add value

Every biosimilar we add to our portfolio provides more patients in more countries with the treatment they need. We are committed to continue investing in biosimillars.

We have one of the industry’s largest and most diverse portfolios: including 20 biosimilars and insulin analogs.

Our portfolio includes many of the top biologics globally and focuses on the areas of oncology, immunology, endocrinology and ophthalmology.

DIABETES & METABOLICS

ONCOLOGY

IMMUNO- LOGY

OPHTHAL- MOLOGY

Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics.

It is projected that biosimilars will generate a savings of $54 billion in direct spending on biologic drugs in the U.S. between 2017 and 2026.

  • A GROWING PORTFOLIO

    We have one of the industry’s largest and most diverse portfolios: including 20 biosimilars and insulin analogs.

    Our portfolio includes many of the top biologics globally and focuses on the areas of oncology, immunology, endocrinology and ophthalmology.

     

  • INDUSTRY-WIDE SAVINGS

    $250 M POTENTIALLY
    SAVED OVER 10 YEARS

    Organizations project that the United States would save $250 billion over ten years if just the 11 likeliest biosimilars would enter the market.

    Express Scripts Biosimilars Progress Today Billions in Savings Tomorrow v0.1 p2.

Biosimilars Value
Biosimilars Value
Hand Biologic
Hand Biologic
Hand Biologic

MANUFACTURING EXPERTISE

experience that counts

Both reference products and biosimilar medicines are made under carefully controlled conditions, known as Good Manufacturing Practices (GMP), to ensure that they are consistently produced to the required quality.

Mylan has made medicines for nearly 60 years and has a long history of manufacturing complex products.

Of our nearly 50 manufacturing sites around the world, 10 focus on product technology development, including biosimilars and respiratory products. One of our state-of-the-art complex analytical laboratories is located in Morgantown, West Virginia and is helping us lead the way in biosimilar development. 

Hand Biologic
Hand Biologic
Hand Biologic
  • CENTERS OF EXCELLENCE

    Manufacture Biosimilar

CONTACT US

we’re easy to access

Address

Corporate Office
Mylan, Inc.
1000 Mylan Boulevard
Canonsburg, PA 15317
Contact Mylan


  • CENTERS OF EXCELLENCE

    AddressCorporate Office Mylan, Inc.
    1000 Mylan Boulevard
    Canonsburg, PA 15317
    Contact Mylan





© 2018 Mylan N.V. All rights reserved.
NON-2018-0965

References:
1. https://biosimilarscouncil.org/resources/whitepaper/#_ftn1
2. IMS data